Douglas Kerr - 04 Dec 2024 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role
Chief Medical Officer
Signature
/s/ Richard Scalzo, Attorney-in-Fact
Issuer symbol
DYN
Transactions as of
04 Dec 2024
Transactions value $
$0
Form type
4
Filing time
06 Dec 2024, 16:05:11 UTC
Previous filing
03 Sep 2024
Next filing
07 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DYN Common Stock Award $0 +48K +101.05% $0.00 95.5K 04 Dec 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DYN Stock option (right to buy) Award $0 +76.6K $0.00 76.6K 04 Dec 2024 Common Stock 76.6K $29.44 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of shares of Common Stock issuable under 48,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 4, 2025.
F2 Includes 95,500 unvested RSUs.
F3 This option was granted on December 4, 2024. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 4, 2028.